The Life Sciences Report
Notable Quotes
"Watch out for NEO; it is significantly undervalued given the opportunities that lie ahead." (7/24/14) NeoGenomics Laboratories - The Life Sciences Report interview with Debjit Chattopadhyay More >
"We feel RXII has largely been ignored by investors, but has potential." (7/10/14) RXi Pharmaceuticals Corp. - The Life Sciences Report Interview with Reni Benjamin More >
"Shiseido's investment in a collaboration with RP is a form of validation for the company." (7/17/14) RepliCel Life Sciences Inc. - The Life Sciences Report interview with Alan Leong More >
"INO's stock could hit double digits pretty easily, in terms of its trading range, with a good outcome from the Phase 2 VGX-3100 study." (6/26/14) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Charles Duncan More >
"We believe BLU has a higher probability of success in its current Phase 3 Kiacta study." (6/12/14) BELLUS Health Inc. - The Life Sciences Report interview with Brian Bloom More >
Companies
| Last: | |||
| Change: | Change(%): | ||
| Volume: | Open: | ||
| High: | Low: | ||
| 52Wk High: | 52Wk Low: | ||
Navidea Biopharmaceuticals Inc.TICKER: NAVB:NYSE
|
A summary of Expert Comments about Navidea Biopharmaceuticals Inc. is currently unavailable. You can find Expert Comments on companies similar to Navidea Biopharmaceuticals Inc. by clicking on the links below.